Archive for 2007/10


MedImmune Presents New Pharmaco-Economic Data At American Academy Of Pediatrics Regarding Infants At High Risk For RSV

MedImmune announced results from a recent economic analysis of Synagis(R) (palivizumab), a monoclonal antibody (MAb) that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in high- risk infants. [click link for full article]
(more...)


10/30/2007 | Respiratory & Asthma | Trackback | Comments Off

CDC Advisory Committee Recommends Nasal Spray Flu Vaccine For Children Ages Two To Five

A panel of immunization experts has voted to expand the recommendation for the nasal spray influenza vaccine, FluMist (MedImmune Vaccines, Inc., Gaithersburg, Md.), to include healthy children from 2 to 5 years of age who are healthy and don't have a history of asthma or wheezing. [click link for full article]
(more...)


10/29/2007 | Respiratory & Asthma | Trackback | Comments Off

Natural Products Association Submits Comments To FDA

The Natural Products Association submitted comments to the U.S. Food and Drug Administration (FDA) surrounding the use of, and forthcoming guidance regarding the Interim Final Rule (IFR) as it relates to the cGMPs. [click link for full article]
(more...)


10/29/2007 | Complememntary & Alternative Medicine | Trackback | Comments Off

RSV Surveillance And Cost-Effectiveness Data Presented By MedImmune

MedImmune, Inc. presented three abstracts at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, adding to the company's growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of hospitalization among infants."MedImmune presented data that provide key insights into how we can optimize the fight against RSV," said Jessie R. Groothuis, M.D., vice president, medical and scientific affairs, infectious disease. [click link for full article]
(more...)


10/29/2007 | Respiratory & Asthma | Trackback | Comments Off

Special Status Given By US And European Regulators To New TB Drug

What: Approximately one-third of the world's population is infected with Mycobacterium tuberculosis, the bacterium that causes TB, and an estimated 1.6 million people died of the disease in 2005. Currently, TB patients must adhere to a complex treatment regimen over a six- to nine-month period. This demanding schedule often results in patients skipping treatment doses, which has given rise to drug-resistant strains of M. [click link for full article]
(more...)


10/27/2007 | Respiratory & Asthma | Trackback | Comments Off

A New Approach For The Treatment Of Community-acquired Pneumonia

Community-acquired pneumonia (CAP) is frequently a severe illness and is the leading cause of death by infectious disease and the sixth leading cause of global mortality in the first world. For this reason, improving the care of adult patients with CAP is one of the focuses of the most important research worldwide. [click link for full article]
(more...)


10/26/2007 | Respiratory & Asthma | Trackback | Comments Off

Antibiotic-Resistant Tuberculosis: Relatively Low Rate In France

Resistance to the antibiotics that specifically target the tuberculosis (TB) bacillus is a severe challenge in developing countries, yet seems relatively uncommon among subjects born in France who have not previously been treated for TB. So concludes an important study by Jérôme Robert and his team (Université Pierre et Marie Curie-Paris 6, Laboratoire de Bactériologie-Hygiène) in the forthcoming issue of the European Respiratory Journal (ERJ). [click link for full article]
(more...)


10/26/2007 | Respiratory & Asthma | Trackback | Comments Off

Sildenafil May Help In Complication After Pulmonary Embolism

About 4% of patients with persistent symptoms after pulmonary embolism develop hypertension in the pulmonary circulation, also called pulmonary hypertension. This is a serious complication leading to disabling symptoms, impaired exercise capacity and increased mortality if left untreated. Some patients might be cured by surgery, but in those not eligible for surgery medical therapy is warranted but not thus far established. [click link for full article]
(more...)


10/26/2007 | Respiratory & Asthma | Trackback | Comments Off

American Lung Association Applauds Release Of Updated CDC Best Practices

The American Lung Association welcomes the update to the Centers for Disease Control and Prevention's (CDC) Best Practices for Comprehensive Tobacco Control Programs. The 2007 edition reinforces the need for states to adequately fund evidence-based tobacco control and prevention programs to reduce the death and disease caused by tobacco use. [click link for full article]
(more...)


10/26/2007 | Respiratory & Asthma | Trackback | Comments Off

Bovine Tuberculosis In Cattle And Badgers, UK

Commenting on the publication last Monday of the Chief Scientific Adviser, Sir David King's report on Bovine TB in Cattle and Badgers BVA President Nick Blayney said: "We welcome this response to the Independent Scientific Group on Cattle TB (ISG) report, not least the conclusion that removal of badgers should take place alongside the continued application of controls on cattle. [click link for full article]
(more...)


10/26/2007 | Respiratory & Asthma | Trackback | Comments Off

« Previous Entries
Next Entries »

© 2006 MBGJ.Org Limited Trading as Natural-Remedies-Clinic

All rights reserved - Designated trademarks and brands are the property of their respective owners

Natural Remedies Clinic - Main Site


Page Sponsors

Thyroid Hair Loss -New Acne Treatments -Lose Weight

>-- Top of Page --<